Horizon Pharma Stock Price, News & Analysis (NASDAQ:HZNP)

$14.84 -0.23 (-1.53 %)
(As of 12/15/2017 05:12 AM ET)
Previous Close$15.07
Today's Range$14.78 - $15.24
52-Week Range$9.45 - $18.31
Volume1.25 million shs
Average Volume3.39 million shs
Market Capitalization$2.46 billion
P/E Ratio10.64
Dividend YieldN/A
Beta1.31

About Horizon Pharma (NASDAQ:HZNP)

Horizon Pharma logoHorizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units. The Company's marketed medicines are ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate & caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% weight per weight (w/w), or PENNSAID 2%, PROCYSBI (cysteamine bitartrate) delayed-release capsules, QUINSAIR (aerosolized form of levofloxacin), RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium).

Receive HZNP News and Ratings via Email

Sign-up to receive the latest news and ratings for HZNP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorHealthcare
SymbolNASDAQ:HZNP
CUSIP44047T10
Phone+353-1-7722100

Debt

Debt-to-Equity Ratio1.89%
Current Ratio1.64%
Quick Ratio1.52%

Price-To-Earnings

Trailing P/E Ratio10.64
Forward P/E Ratio20.61
P/E Growth1.24

Sales & Book Value

Annual Sales$981.12 million
Price / Sales2.48
Cash Flow$3.14 per share
Price / Cash4.73
Book Value$7.84 per share
Price / Book1.89

Profitability

Trailing EPS($3.04)
Net Income$-166,830,000.00
Net Margins-45.28%
Return on Equity20.22%
Return on Assets5.35%

Miscellaneous

Employees1,050
Outstanding Shares163,890,000

Horizon Pharma (NASDAQ:HZNP) Frequently Asked Questions

What is Horizon Pharma's stock symbol?

Horizon Pharma trades on the NASDAQ under the ticker symbol "HZNP."

How will Horizon Pharma's stock buyback program work?

Horizon Pharma announced that its Board of Directors has initiated a stock repurchase plan on Sunday, June 4th 2017, which authorizes the company to repurchase 1,000% of shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase shares of its stock through open market purchases. Stock repurchase plans are generally an indication that the company's management believes its shares are undervalued.

How were Horizon Pharma's earnings last quarter?

Horizon Pharma PLC (NASDAQ:HZNP) issued its quarterly earnings data on Monday, November, 6th. The biopharmaceutical company reported $0.26 earnings per share for the quarter, topping analysts' consensus estimates of $0.22 by $0.04. The biopharmaceutical company earned $271.60 million during the quarter, compared to analysts' expectations of $259.74 million. Horizon Pharma had a positive return on equity of 20.22% and a negative net margin of 45.28%. The company's revenue was up 30.1% on a year-over-year basis. During the same period in the previous year, the business earned $0.70 EPS. View Horizon Pharma's Earnings History.

When will Horizon Pharma make its next earnings announcement?

Horizon Pharma is scheduled to release their next quarterly earnings announcement on Monday, February, 26th 2018. View Earnings Estimates for Horizon Pharma.

Where is Horizon Pharma's stock going? Where will Horizon Pharma's stock price be in 2017?

11 analysts have issued 12 month target prices for Horizon Pharma's stock. Their forecasts range from $12.00 to $30.00. On average, they anticipate Horizon Pharma's stock price to reach $18.64 in the next twelve months. View Analyst Ratings for Horizon Pharma.

What are Wall Street analysts saying about Horizon Pharma stock?

Here are some recent quotes from research analysts about Horizon Pharma stock:

  • 1. According to Zacks Investment Research, "Horizon has been focused on expanding its orphan drug business.The company has been quite active on the acquisition front over the past few quarters. However, revenues from primary care business units declined due to the implementation of a new commercial model where the company is contracting with pharmacy benefit managers and payers to help patients obtain access to its medicines. Moreover, in Jun 2017, Horizon Pharma sold the marketing rights for Procysbi and Quinsair in the Europe, the Middle East and Africa regions to Chiesi Farmaceutici S.p.A. as the company focuses on higher-return businesses. Shares of the company have underperformed the industry. With the company’s efforts to expand Actimmune’s label suffered a setback, focus will be on Krystexxa’s performance. Stiff competition for drugs will also impact sales." (10/10/2017)
  • 2. Cantor Fitzgerald analysts commented, "We are maintaining our Overweight rating and $17, 12 month PT for HZNP shares, but lowering our 2017 and 2018 EPS estimates because we have taken out some sales for the Raptor franchise now that Horizon has completed the sale of its EU marketing rights to Chiesi (Not Covered). We continue to expect Krystexxa sales to be impacted by the 340b program in 4Q17, which could prove conservative. Please see our note for details Potential HHS Delay Could Be Positive for HZNP’s Krystexxa Sales This Year. We expect orphan drug sales to increase 50% YOY which is in line with Horizon’s guidance, and rheumatology sales to increase 37% YOY, which is also roughly in line with Horizon’s guidance. Valuation. We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $17." (9/11/2017)
  • 3. Piper Jaffray Companies analysts commented, "We had the opportunity to travel with Horizon senior management in meetings with investors. We gained additional insight into Pennsaid 2% and Ravicti, and also came away with insights into management's latest thinking regarding M&A. Though there are undoubtedly some headwinds facing the primary care segment, we believe that this segment should be on largely stable footing over the long-term given HZNP's payer contracting efforts. That dynamic combined with continued strength from the rare disease segment points to a long-term EPS CAGR (2017-2022) in the mid-teens, and should translate into multiple expansion with a 2017E P/E currently at 7x. We reiterate our Overweight rating and are lowering our PT to $30 from $32 (see below for more details)." (3/24/2017)
  • 4. Guggenheim analysts commented, "HZNP reported a 4Q16 beat, underscoring our confidence that HZNP can continue to meet or exceed earnings expectations in '17+. Post 4Q16, we think that the peak sales potential of Pennsaid 2%, Procysbi, and Krystexxa are underappreciated, with additional earnings upside potentially coming from M&A as HZNP redeploys cash generated by its Primary Care ("PC") business into business development focused on orphan and rare disease indication medicines. While concerns remain over growth prospects for HZNP's PC business, Ravicti and Actimmune, these assets continue to generate meaningful cash to fuel HZNP's growth aspiration of $2B in sales by 2020." (2/27/2017)
  • 5. Mizuho analysts commented, "We are positive on HZNP ahead of the February 27 earnings call: We think the company may deliver a 4Q:16 earnings beat. We model 4Q:16 revenues of $325.4M and EPS of $0.57 relative to consensus $308.5M and $0.50 and implied guidance $309-$314M. Horizon has delivered strong beats in the past and we expect adjusted EBITDA to approach the higher end of the guidance range of $450-$460M. With respect to 2017 guidance, we fall below FactSet consensus estimates of $1,289.7M and $2.39 (we model $1,281.8M and $2.29), but note that Horizon may be able to beat this range via a combination of both price and volume growth, so guidance could come in stronger than expected. There is still significant uncertainty around business operation under the new PBM contracts, gross to net discounts, infrastructure needs, and the timing of anticipated volume growth. We therefore expect the focus of the call to be around these issues as well as on future business development targets and pipeline outlook." (2/22/2017)

Who are some of Horizon Pharma's key competitors?

Who are Horizon Pharma's key executives?

Horizon Pharma's management team includes the folowing people:

  • Timothy P. Walbert, Chairman of the Board, President, Chief Executive Officer (Age 50)
  • Paul W. Hoelscher, Chief Financial Officer, Executive Vice President (Age 52)
  • Barry J. Moze, Executive Vice President, Chief Administrative Officer (Age 63)
  • Brian K. Beeler, Executive Vice President, General Counsel (Age 44)
  • Robert F. Carey, Executive Vice President, Chief Business Officer (Age 58)
  • Michael A. DesJardin, Executive Vice President - Technical Operations (Age 59)
  • George P. Hampton, Executive Vice President - Primary Care Business Unit (Age 47)
  • David A. Happel, Executive Vice President - Orphan Business Unit (Age 54)
  • Jeffrey W. Sherman M.D., Executive Vice President - Research and Development and Chief Medical Officer (Age 62)
  • Vikram Karnani, Senior Vice President - Rheumatology Business Unit (Age 42)

Who owns Horizon Pharma stock?

Horizon Pharma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Dimensional Fund Advisors LP (4.54%), JPMorgan Chase & Co. (2.10%), Ameriprise Financial Inc. (1.30%), Rothschild Asset Management Inc. (1.10%), Bank of New York Mellon Corp (0.61%) and Schwab Charles Investment Management Inc. (0.52%). Company insiders that own Horizon Pharma stock include Jeffrey W Sherman, Michael G Grey, Robert Carey and Virinder Nohria. View Institutional Ownership Trends for Horizon Pharma.

Who sold Horizon Pharma stock? Who is selling Horizon Pharma stock?

Horizon Pharma's stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Schwab Charles Investment Management Inc., Deltec Asset Management LLC, American Century Companies Inc., OxFORD Asset Management LLP, Stifel Financial Corp, California State Teachers Retirement System and Nationwide Fund Advisors. View Insider Buying and Selling for Horizon Pharma.

Who bought Horizon Pharma stock? Who is buying Horizon Pharma stock?

Horizon Pharma's stock was acquired by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., Dimensional Fund Advisors LP, Principal Financial Group Inc., Rothschild Asset Management Inc., Sei Investments Co., Chicago Equity Partners LLC, Cornerstone Capital Management Holdings LLC. and Wells Fargo & Company MN. View Insider Buying and Selling for Horizon Pharma.

How do I buy Horizon Pharma stock?

Shares of Horizon Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Horizon Pharma's stock price today?

One share of Horizon Pharma stock can currently be purchased for approximately $14.84.

How big of a company is Horizon Pharma?

Horizon Pharma has a market capitalization of $2.46 billion and generates $981.12 million in revenue each year. The biopharmaceutical company earns $-166,830,000.00 in net income (profit) each year or ($3.04) on an earnings per share basis. Horizon Pharma employs 1,050 workers across the globe.

How can I contact Horizon Pharma?

Horizon Pharma's mailing address is Dublin 4 1st Fl 1 Burlington Road, Connaught House, DUBLIN, HM 09, Ireland. The biopharmaceutical company can be reached via phone at +353-1-7722100 or via email at [email protected]


MarketBeat Community Rating for Horizon Pharma (HZNP)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  542 (Vote Outperform)
Underperform Votes:  207 (Vote Underperform)
Total Votes:  749
MarketBeat's community ratings are surveys of what our community members think about Horizon Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Horizon Pharma (NASDAQ:HZNP) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.832.832.832.83
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $19.75$19.75$20.00$20.42
Price Target Upside: 37.34% upside37.63% upside42.35% upside100.16% upside

Horizon Pharma (NASDAQ:HZNP) Consensus Price Target History

Price Target History for Horizon Pharma (NASDAQ:HZNP)

Horizon Pharma (NASDAQ:HZNP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/1/2017Cantor FitzgeraldSet Price TargetBuy$17.00LowView Rating Details
11/7/2017Jefferies GroupBoost Price TargetBuy$16.00 -> $21.00N/AView Rating Details
10/22/2017Stifel NicolausReiterated RatingBuy$20.00N/AView Rating Details
10/15/2017Piper Jaffray CompaniesSet Price TargetBuy$18.00N/AView Rating Details
9/28/2017CowenReiterated RatingBuyLowView Rating Details
9/28/2017Goldman Sachs GroupInitiated CoverageBuy -> Buy$16.00MediumView Rating Details
8/28/2017MizuhoReiterated RatingHold$9.00 -> $12.00MediumView Rating Details
8/10/2017BMO Capital MarketsReiterated RatingOutperform$17.00 -> $18.00HighView Rating Details
5/9/2017CitigroupLower Price TargetBuy$20.00 -> $13.00MediumView Rating Details
2/28/2017Morgan StanleyReiterated RatingEqual Weight$20.00N/AView Rating Details
2/27/2017GuggenheimInitiated CoverageBuy$30.00N/AView Rating Details
9/12/2016Brean CapitalReiterated RatingBuy$32.00N/AView Rating Details
(Data available from 12/15/2015 forward)

Earnings

Horizon Pharma (NASDAQ:HZNP) Earnings History and Estimates Chart

Earnings by Quarter for Horizon Pharma (NASDAQ:HZNP)

Horizon Pharma (NASDAQ HZNP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/5/2018$0.23N/AView Earnings Details
11/6/2017Q3 2017$0.22$0.26$259.74 million$271.60 millionViewN/AView Earnings Details
8/7/2017Q2 2017$0.12$0.41$237.01 million$289.51 millionViewListenView Earnings Details
5/8/2017Q1 2017$0.25$0.21$248.71 million$220.90 millionViewListenView Earnings Details
2/27/2017Q416$0.51$0.64$307.93 million$310.30 millionViewListenView Earnings Details
11/7/2016Q316$0.63$0.70$270.04 million$273.70 millionViewListenView Earnings Details
8/8/2016Q216$0.50$0.62$235.43 million$257.40 millionViewN/AView Earnings Details
5/9/2016Q116$0.30$0.34$197.73 million$204.70 millionViewN/AView Earnings Details
2/29/2016Q415$0.62$0.63$240.92 million$244.50 millionViewListenView Earnings Details
11/6/2015Q315$0.41$0.59$185.70 million$292.70 millionViewListenView Earnings Details
8/7/2015Q215$0.32$0.39$156.41 million$172.80 millionViewListenView Earnings Details
5/8/2015Q115$0.22$0.16$104.20 million$113.10 millionViewN/AView Earnings Details
2/27/2015Q414$0.23$0.27$95.50 million$103.80 millionViewN/AView Earnings Details
11/6/2014Q314$0.19$0.24$73.17 million$75.10 millionViewN/AView Earnings Details
8/7/2014Q214$0.16$0.14$58.35 million$66.10 millionViewN/AView Earnings Details
5/9/2014Q114$0.01$0.10$42.69 million$51.90 millionViewN/AView Earnings Details
3/13/2014Q413($0.08)($0.22)$32.20 million$43.10 millionViewN/AView Earnings Details
11/8/2013Q3 13($0.25)($0.03)$18.31 million$31.50 millionViewN/AView Earnings Details
8/9/2013Q213($0.32)($0.24)$16.09 million$17.64 millionViewN/AView Earnings Details
5/10/2013Q113($0.35)($0.30)$9.47 million$9.20 millionViewN/AView Earnings Details
11/13/2012Q312($0.68)($0.39)$4.12 million$7.20 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Horizon Pharma (NASDAQ:HZNP) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171$0.10$0.10$0.10
Q3 20171$0.19$0.19$0.19
Q4 20171$0.22$0.22$0.22
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Horizon Pharma (NASDAQ:HZNP)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Horizon Pharma (NASDAQ HZNP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.20%
Institutional Ownership Percentage: 86.59%
Insider Trades by Quarter for Horizon Pharma (NASDAQ:HZNP)
Institutional Ownership by Quarter for Horizon Pharma (NASDAQ:HZNP)

Horizon Pharma (NASDAQ HZNP) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/10/2017Michael G GreyDirectorBuy10,000$9.48$94,800.00View SEC Filing  
3/1/2017Robert CareyEVPSell31,808$16.03$509,882.24View SEC Filing  
8/2/2016Jeffrey W. ShermanEVPSell2,900$20.00$58,000.00View SEC Filing  
6/15/2016Virinder NohriaDirectorSell25,000$17.69$442,250.00View SEC Filing  
2/26/2016Jeffrey W ShermanEVPSell4,100$20.00$82,000.00View SEC Filing  
12/10/2015Jeffrey W ShermanEVPSell4,456$20.00$89,120.00View SEC Filing  
9/21/2015Jeffrey W ShermanEVPSell7,750$31.78$246,295.00View SEC Filing  
7/15/2015Jeffrey W ShermanEVPSell26,887$35.55$955,832.85View SEC Filing  
3/13/2015Jeff HimawanDirectorSell554,564$22.44$12,444,416.16View SEC Filing  
3/10/2015Jeff HimawanDirectorSell1,614,827$21.85$35,283,969.95View SEC Filing  
11/19/2014Jeff HimawanDirectorSell3,450,000$12.05$41,572,500.00View SEC Filing  
11/19/2014Jeffrey W ShermanEVPSell24,999$12.05$301,237.95View SEC Filing  
11/19/2014Timothy P WalbertCEOSell150,000$12.05$1,807,500.00View SEC Filing  
11/13/2014Balaji VenkataramanMajor ShareholderSell6,086,957$11.54$70,243,483.78View SEC Filing  
11/13/2014Virinder NohriaDirectorSell1,739,130$11.54$20,069,560.20View SEC Filing  
9/30/2014Vaere Robert J DeCFOSell51,942$12.28$637,847.76View SEC Filing  
5/19/2014Timothy WalbertCEOSell31,742$12.94$410,741.48View SEC Filing  
5/19/2014Todd SmithEVPSell10,159$12.94$131,457.46View SEC Filing  
5/19/2014Vaere Robert DeCFOSell12,939$12.94$167,430.66View SEC Filing  
12/13/2013Jeffrey BirdDirectorBuy668,673$6.50$4,346,374.50View SEC Filing  
12/9/2013Timothy WalbertCEOSell12,124$6.79$82,321.96View SEC Filing  
12/9/2013Todd SmithEVPSell11,322$6.91$78,235.02View SEC Filing  
11/21/2013Jeffrey BirdDirectorBuy151,089$6.24$942,795.36View SEC Filing  
9/25/2012Jeffrey W BirdDirectorBuy575,356$3.49$2,007,992.44View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Horizon Pharma (NASDAQ HZNP) News Headlines

Source:
DateHeadline
Horizon Pharma Earns RS Rating UpgradeHorizon Pharma Earns RS Rating Upgrade
finance.yahoo.com - December 14 at 3:21 PM
ETFs with exposure to Horizon Pharma Plc : December 4, 2017ETFs with exposure to Horizon Pharma Plc : December 4, 2017
finance.yahoo.com - December 4 at 3:19 PM
$267.58 Million in Sales Expected for Horizon Pharma PLC (HZNP) This Quarter$267.58 Million in Sales Expected for Horizon Pharma PLC (HZNP) This Quarter
www.americanbankingnews.com - December 3 at 2:20 AM
 Brokerages Expect Horizon Pharma PLC (HZNP) to Announce $0.22 Earnings Per Share Brokerages Expect Horizon Pharma PLC (HZNP) to Announce $0.22 Earnings Per Share
www.americanbankingnews.com - December 1 at 11:34 PM
Horizon Pharma (HZNP) Given a $17.00 Price Target by Cantor Fitzgerald AnalystsHorizon Pharma (HZNP) Given a $17.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - December 1 at 4:12 PM
Horizon Pharma plc to Participate in BMO Prescriptions for Success Healthcare ConferenceHorizon Pharma plc to Participate in BMO Prescriptions for Success Healthcare Conference
finance.yahoo.com - December 1 at 7:12 AM
Horizon Pharma PLC (HZNP) Given Average Rating of "Buy" by BrokeragesHorizon Pharma PLC (HZNP) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - November 30 at 2:18 PM
Horizon Pharma (HZNP) Given "Buy" Rating at UBSHorizon Pharma (HZNP) Given "Buy" Rating at UBS
www.americanbankingnews.com - November 30 at 7:34 AM
Horizon Pharma plc Names Shao-Lee Lin, MD, Ph.D. Executive Vice President, Research and Development and Chief ... - GlobeNewswire (press release)Horizon Pharma plc Names Shao-Lee Lin, MD, Ph.D. Executive Vice President, Research and Development and Chief ... - GlobeNewswire (press release)
globenewswire.com - November 30 at 6:48 AM
Horizon Pharma plc Names Shao-Lee Lin, M.D., Ph.D. Executive Vice President, Research and Development and Chief Scientific OfficerHorizon Pharma plc Names Shao-Lee Lin, M.D., Ph.D. Executive Vice President, Research and Development and Chief Scientific Officer
finance.yahoo.com - November 30 at 6:48 AM
Nuvo Pharmaceuticals™ Commences Trading on the OTCQX® Market in the U.S.Nuvo Pharmaceuticals™ Commences Trading on the OTCQX® Market in the U.S.
finance.yahoo.com - November 28 at 9:29 AM
ETFs with exposure to Horizon Pharma Plc : November 24, 2017ETFs with exposure to Horizon Pharma Plc : November 24, 2017
finance.yahoo.com - November 24 at 4:55 PM
Nuvo Pharmaceuticals™ Announces Appointment of Jesse Ledger as President & Chief Executive OfficerNuvo Pharmaceuticals™ Announces Appointment of Jesse Ledger as President & Chief Executive Officer
finance.yahoo.com - November 23 at 1:44 AM
ETFs with exposure to Horizon Pharma Plc : November 13, 2017ETFs with exposure to Horizon Pharma Plc : November 13, 2017
finance.yahoo.com - November 13 at 7:43 PM
 Brokerages Anticipate Horizon Pharma PLC (HZNP) to Announce $0.22 Earnings Per Share Brokerages Anticipate Horizon Pharma PLC (HZNP) to Announce $0.22 Earnings Per Share
www.americanbankingnews.com - November 13 at 3:31 PM
Horizon Pharma Plc breached its 50 day moving average in a Bearish Manner : HZNP-US : November 10, 2017Horizon Pharma Plc breached its 50 day moving average in a Bearish Manner : HZNP-US : November 10, 2017
finance.yahoo.com - November 11 at 10:34 AM
Horizon Pharma plc Selected as One of Chicago’s Top Workplaces by the Chicago TribuneHorizon Pharma plc Selected as One of Chicago’s Top Workplaces by the Chicago Tribune
finance.yahoo.com - November 11 at 10:34 AM
Horizon Pharma Plc :HZNP-US: Earnings Analysis: Q3, 2017 By the Numbers : November 10, 2017Horizon Pharma Plc :HZNP-US: Earnings Analysis: Q3, 2017 By the Numbers : November 10, 2017
finance.yahoo.com - November 11 at 10:34 AM
FY2018 EPS Estimates for Horizon Pharma PLC Increased by Cantor Fitzgerald (HZNP)FY2018 EPS Estimates for Horizon Pharma PLC Increased by Cantor Fitzgerald (HZNP)
www.americanbankingnews.com - November 10 at 5:40 PM
Horizon Pharma PLC (HZNP) Expected to Earn FY2017 Earnings of $0.71 Per ShareHorizon Pharma PLC (HZNP) Expected to Earn FY2017 Earnings of $0.71 Per Share
www.americanbankingnews.com - November 10 at 7:40 AM
Traders Purchase Large Volume of Horizon Pharma PLC Put Options (HZNP)Traders Purchase Large Volume of Horizon Pharma PLC Put Options (HZNP)
www.americanbankingnews.com - November 10 at 1:08 AM
Horizon Pharma PLC (HZNP) Expected to Earn Q4 2017 Earnings of $0.22 Per ShareHorizon Pharma PLC (HZNP) Expected to Earn Q4 2017 Earnings of $0.22 Per Share
www.americanbankingnews.com - November 9 at 9:58 AM
Horizon Pharma plc Presents New Data at 2017 ACR/ARHP Annual Meeting, Advances ...Horizon Pharma plc Presents New Data at 2017 ACR/ARHP Annual Meeting, Advances ...
globenewswire.com - November 7 at 2:46 AM
Horizon Pharma Plc to Host Earnings CallHorizon Pharma Plc to Host Earnings Call
finance.yahoo.com - November 7 at 2:46 AM
Horizon Pharma plc Announces Third-Quarter and Year-to-Date 2017 ResultsHorizon Pharma plc Announces Third-Quarter and Year-to-Date 2017 Results
finance.yahoo.com - November 7 at 2:46 AM
Horizon Pharma reports 3Q lossHorizon Pharma reports 3Q loss
finance.yahoo.com - November 7 at 2:46 AM
Horizon (HZNP) Tops Q3 Earnings, Shares UpHorizon (HZNP) Tops Q3 Earnings, Shares Up
finance.yahoo.com - November 7 at 2:46 AM
Horizon Pharma plc Presents New Data at 2017 ACR/ARHP Annual Meeting, Advances Clinical Understanding of KRYSTEXXA® (pegloticase injection) in Adults with Uncontrolled GoutHorizon Pharma plc Presents New Data at 2017 ACR/ARHP Annual Meeting, Advances Clinical Understanding of KRYSTEXXA® (pegloticase injection) in Adults with Uncontrolled Gout
finance.yahoo.com - November 7 at 2:46 AM
Edited Transcript of HZNP earnings conference call or presentation 6-Nov-17 1:00pm GMTEdited Transcript of HZNP earnings conference call or presentation 6-Nov-17 1:00pm GMT
finance.yahoo.com - November 7 at 2:46 AM
Horizon Pharma PLC (HZNP) Releases  Earnings Results, Beats Estimates By $0.04 EPSHorizon Pharma PLC (HZNP) Releases Earnings Results, Beats Estimates By $0.04 EPS
www.americanbankingnews.com - November 6 at 10:09 AM
How Financially Strong Is Horizon Pharma Public Limited Company (HZNP)?How Financially Strong Is Horizon Pharma Public Limited Company (HZNP)?
finance.yahoo.com - November 6 at 12:13 AM
Horizon Pharma plc Presents Results from an Open-Label Study on the Use of ...Horizon Pharma plc Presents Results from an Open-Label Study on the Use of ...
www.nasdaq.com - November 5 at 7:11 PM
Horizon Pharma PLC (HZNP) Receives Consensus Recommendation of "Buy" from BrokeragesHorizon Pharma PLC (HZNP) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - November 5 at 11:06 AM
Horizon Pharma plc Announces Poster Presentation on KRYSTEXXA® (pegloticase injection) at the American Society ... - GlobeNewswire (press release)Horizon Pharma plc Announces Poster Presentation on KRYSTEXXA® (pegloticase injection) at the American Society ... - GlobeNewswire (press release)
globenewswire.com - November 5 at 2:27 AM
Horizon Pharma plc Presents Results from an Open-Label Study on the Use of PROCYSBI® (cysteamine bitartrate) Delayed-Release Capsules in Treatment-Naïve Children Younger than 6 Years of AgeHorizon Pharma plc Presents Results from an Open-Label Study on the Use of PROCYSBI® (cysteamine bitartrate) Delayed-Release Capsules in Treatment-Naïve Children Younger than 6 Years of Age
finance.yahoo.com - November 5 at 2:27 AM
Horizon Pharma plc Announces Poster Presentation on KRYSTEXXA® (pegloticase injection) at the American Society of Nephrology Kidney Week 2017Horizon Pharma plc Announces Poster Presentation on KRYSTEXXA® (pegloticase injection) at the American Society of Nephrology Kidney Week 2017
finance.yahoo.com - November 4 at 1:38 AM
GURUs Holdings Imply 10% Gain Potential - NasdaqGURU's Holdings Imply 10% Gain Potential - Nasdaq
www.nasdaq.com - November 3 at 8:00 AM
Horizon Pharma (HZNP) Q3 Earnings: A Disappointment in Store? (revised) - NasdaqHorizon Pharma (HZNP) Q3 Earnings: A Disappointment in Store? (revised) - Nasdaq
www.nasdaq.com - November 3 at 8:00 AM
Horizon Pharma plc to Participate in Investor Conferences in November - GlobeNewswire (press release)Horizon Pharma plc to Participate in Investor Conferences in November - GlobeNewswire (press release)
globenewswire.com - November 3 at 8:00 AM
Horizon Pharma (HZNP) Q3 Earnings: A Disappointment in Store? (revised)Horizon Pharma (HZNP) Q3 Earnings: A Disappointment in Store? (revised)
finance.yahoo.com - November 3 at 8:00 AM
Horizon Pharma plc to Participate in Investor Conferences in NovemberHorizon Pharma plc to Participate in Investor Conferences in November
finance.yahoo.com - November 3 at 8:00 AM
Nuvo Pharmaceuticals™ Announces 2017 Third Quarter ResultsNuvo Pharmaceuticals™ Announces 2017 Third Quarter Results
finance.yahoo.com - November 2 at 1:32 AM
Horizon Pharma PLC (HZNP) Scheduled to Post Earnings on MondayHorizon Pharma PLC (HZNP) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - October 30 at 11:52 AM
Horizon Pharma plc to Leverage Medidata Clinical Cloud® and eTMF Solutions to Support its Business TransformationHorizon Pharma plc to Leverage Medidata Clinical Cloud® and eTMF Solutions to Support its Business Transformation
finance.yahoo.com - October 27 at 6:28 AM
Horizon Pharma plc (HZNP) Reports Availability of PROCYSBI (cysteamine bitartrate) in CanadaHorizon Pharma plc (HZNP) Reports Availability of PROCYSBI (cysteamine bitartrate) in Canada
www.streetinsider.com - October 27 at 6:28 AM
Short Interest in Horizon Pharma PLC (HZNP) Decreases By 10.2%Short Interest in Horizon Pharma PLC (HZNP) Decreases By 10.2%
www.americanbankingnews.com - October 27 at 1:40 AM
Horizon Pharma plc to Leverage Medidata Clinical Cloud® and eTMF Solutions to Support its Business Transformation - Business Wire (press release)Horizon Pharma plc to Leverage Medidata Clinical Cloud® and eTMF Solutions to Support its Business Transformation - Business Wire (press release)
www.businesswire.com - October 26 at 12:30 PM
Horizon Pharma (HZNP) Reports First Patient Enrolled in Confirmatory Phase 3 Clinical Trial - StreetInsider.comHorizon Pharma (HZNP) Reports First Patient Enrolled in Confirmatory Phase 3 Clinical Trial - StreetInsider.com
www.streetinsider.com - October 26 at 12:29 PM
Horizon Pharma plc (HZNP) Reports Availability of PROCYSBI (cysteamine bitartrate) in Canada - StreetInsider.comHorizon Pharma plc (HZNP) Reports Availability of PROCYSBI (cysteamine bitartrate) in Canada - StreetInsider.com
www.streetinsider.com - October 26 at 12:29 PM
Horizon Pharma plc Announces First Patient Enrolled in Confirmatory Phase 3 Clinical Trial Evaluating Teprotumumab for the Treatment of Moderate-to-Severe Active Thyroid Eye DiseaseHorizon Pharma plc Announces First Patient Enrolled in Confirmatory Phase 3 Clinical Trial Evaluating Teprotumumab for the Treatment of Moderate-to-Severe Active Thyroid Eye Disease
finance.yahoo.com - October 26 at 12:29 PM

SEC Filings

Horizon Pharma (NASDAQ:HZNP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Horizon Pharma (NASDAQ:HZNP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Horizon Pharma (NASDAQ HZNP) Stock Chart for Friday, December, 15, 2017

Loading chart…

This page was last updated on 12/15/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.